Category Archives: Antibody Engineering R&D

30Mar/24

CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer

March 30, 2024Antibody Engineering R&D, Cancer ImmunotherapyColorectal Cancer, Targeting CD73biorab

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, with the likelihood of distant metastasis to the liver or lungs adding to the challenges of CRC treatment. Currently, surgical resectionRead More…

15Jul/21

Pattern and Trend of Therapeutic Antibody Discovery

July 15, 2021Antibody Engineering R&D, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…

05Jan/18

MGH team engineers anti-inflammatory antibodies that may treat autoimmune disease

January 5, 2018Antibody Engineering R&D, Newsantibody discoverybiorab

“A team of investigators has found a way to engineer antibodies within an organism, converting autoantibodies that attack ‘self’ tissues into anti-inflammatory antibodies in animal models of two autoimmune diseases.” A teamRead More…